首页> 美国卫生研究院文献>Frontiers in Public Health >Innovative Programmable Bio-Nano-Chip Digitizes Biology Using Sensors That Learn Bridging Biomarker Discovery and Clinical Implementation
【2h】

Innovative Programmable Bio-Nano-Chip Digitizes Biology Using Sensors That Learn Bridging Biomarker Discovery and Clinical Implementation

机译:创新的可编程生物纳米芯片使用了解桥接生物标志物发现和临床实施的传感器将生物学数字化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The lack of standard tools and methodologies and the absence of a streamlined multimarker approval process have hindered the translation rate of new biomarkers into clinical practice for a variety of diseases afflicting humankind. Advanced novel technologies with superior analytical performance and reduced reagent costs, like the programmable bio-nano-chip system featured in this article, have potential to change the delivery of healthcare. This universal platform system has the capacity to digitize biology, resulting in a sensor modality with a capacity to learn. With well-planned device design, development, and distribution plans, there is an opportunity to translate benchtop discoveries in the genomics, proteomics, metabolomics, and glycomics fields by transforming the information content of key biomarkers into actionable signatures that can empower physicians and patients for a better management of healthcare. While the process is complicated and will take some time, showcased here are three application areas for this flexible platform that combines biomarker content with minimally invasive or non-invasive sampling, such as brush biopsy for oral cancer risk assessment; serum, plasma, and small volumes of blood for the assessment of cardiac risk and wellness; and oral fluid sampling for drugs of abuse testing at the point of need.
机译:缺乏标准的工具和方法,以及缺乏简化的多标志物批准程序,已经阻碍了新的生物标志物向多种人类疾病转化为临床实践的转化率。具有卓越分析性能和降低试剂成本的先进新颖技术(如本文中介绍的可编程生物纳米芯片系统)具有改变医疗保健服务的潜力。这个通用平台系统具有将生物学数字化的能力,从而产生了具有学习能力的传感器形态。通过精心计划的设备设计,开发和分配计划,有机会将关键生物标志物的信息内容转换为可操作的签名,从而使医师和患者有能力进行研究,从而将他们的研究成果转化为基因组学,蛋白质组学,代谢组学和糖组学领域的新发现。更好的医疗保健管理。尽管该过程很复杂且需要一段时间,但此处展示的是该灵活平台的三个应用领域,该平台将生物标志物的内容与微创或无创采样(例如用于口腔癌风险评估的刷式活检)相结合;血清,血浆和少量血液,用于评估心脏风险和健康状况;以及在需要时进行滥用药物测试的口服液采样。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号